Bank of New York Mellon Corp Buys 56,054 Shares of Vaxcyte, Inc. (NASDAQ:PCVX)

Bank of New York Mellon Corp raised its stake in shares of Vaxcyte, Inc. (NASDAQ:PCVX) by 13.6% in the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 468,579 shares of the company’s stock after buying an additional 56,054 shares during the period. Bank of New York Mellon Corp’s holdings in Vaxcyte were worth $35,382,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also recently modified their holdings of PCVX. Darwin Global Management Ltd. boosted its holdings in shares of Vaxcyte by 374.3% in the first quarter. Darwin Global Management Ltd. now owns 2,750,804 shares of the company’s stock worth $187,907,000 after buying an additional 2,170,845 shares during the last quarter. Vanguard Group Inc. raised its position in Vaxcyte by 15.2% in the first quarter. Vanguard Group Inc. now owns 9,737,254 shares of the company’s stock worth $665,152,000 after acquiring an additional 1,284,883 shares during the period. Norges Bank purchased a new position in shares of Vaxcyte during the 4th quarter worth $57,494,000. Capital Research Global Investors grew its position in shares of Vaxcyte by 20.4% during the 1st quarter. Capital Research Global Investors now owns 4,140,521 shares of the company’s stock valued at $282,839,000 after acquiring an additional 700,414 shares during the period. Finally, Janus Henderson Group PLC increased its stake in shares of Vaxcyte by 9.9% in the 1st quarter. Janus Henderson Group PLC now owns 7,673,868 shares of the company’s stock worth $524,117,000 after purchasing an additional 692,492 shares in the last quarter. 96.78% of the stock is owned by institutional investors.

Vaxcyte Price Performance

Shares of NASDAQ PCVX opened at $80.76 on Tuesday. The stock has a market cap of $9.01 billion, a PE ratio of -18.87 and a beta of 0.97. Vaxcyte, Inc. has a 1 year low of $44.20 and a 1 year high of $87.71. The firm has a fifty day moving average price of $79.01 and a 200-day moving average price of $72.51.

Vaxcyte (NASDAQ:PCVX) last issued its earnings results on Tuesday, August 6th. The company reported ($1.10) earnings per share for the quarter, missing the consensus estimate of ($0.98) by ($0.12). During the same period in the prior year, the company earned ($0.70) EPS. On average, research analysts expect that Vaxcyte, Inc. will post -4.33 EPS for the current year.

Analyst Ratings Changes

PCVX has been the topic of several analyst reports. Cantor Fitzgerald reiterated an “overweight” rating on shares of Vaxcyte in a research report on Thursday, June 20th. Needham & Company LLC reaffirmed a “buy” rating and issued a $95.00 price objective on shares of Vaxcyte in a research note on Wednesday, August 7th.

Insider Transactions at Vaxcyte

In related news, SVP Mikhail Eydelman sold 1,667 shares of Vaxcyte stock in a transaction that occurred on Monday, July 1st. The stock was sold at an average price of $76.37, for a total transaction of $127,308.79. Following the sale, the senior vice president now owns 30,826 shares of the company’s stock, valued at approximately $2,354,181.62. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In other news, SVP Mikhail Eydelman sold 1,667 shares of the business’s stock in a transaction on Monday, July 1st. The shares were sold at an average price of $76.37, for a total value of $127,308.79. Following the transaction, the senior vice president now owns 30,826 shares of the company’s stock, valued at $2,354,181.62. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, CEO Grant Pickering sold 15,000 shares of Vaxcyte stock in a transaction on Monday, June 24th. The shares were sold at an average price of $75.64, for a total transaction of $1,134,600.00. Following the completion of the sale, the chief executive officer now owns 478,888 shares in the company, valued at $36,223,088.32. The disclosure for this sale can be found here. Insiders sold a total of 70,283 shares of company stock valued at $5,613,568 over the last 90 days. Company insiders own 3.10% of the company’s stock.

Vaxcyte Profile

Vaxcyte, Inc, a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness.